Molecular Formula | C27H30N2O2 |
Molar Mass | 414.54 |
Density | 1.11 |
Melting Point | 249-252°C |
Boling Point | 592.3±50.0 °C(Predicted) |
Solubility | DMSO (Slightly), Ethyl Acetate (Slightly, Heated), Methanol (Slightly, Heated) |
Appearance | Solid |
Color | White to Off-White |
pKa | 4.26±0.10(Predicted) |
Storage Condition | Refrigerator |
In vivo study | Palovarotene suppresses post-traumatic chondrogenesis and osteogenesis and mitigated trauma-induced ectopic bone formation. Palovarotene inhibits subcutaneous and intramuscular heterotopic ossification (HO) in mice. Palovarotene is given orally for 14 days at 1 mg/kg/day starting on post-operative day (POD) 1 or POD-5, and HO amount, wound dehiscence and related processes are monitored for up to 84 days post injury. Compared to vehicle-control animals, Palovarotene significantly decreases HO by 50 to 60% regardless of when the treatment started and if infection is present. Starting from day 1 of injury, half of the Acvr1 cR206H/+ mice are treated with Palovarotene by daily gavage for 14 days and the other half received vehicle as control. Analysis by mCT and 3D image reconstruction at day 14 shows that large HO tissue masses have formed in the targeted leg of Acvr1 cR206H/+ mutant mice receiving vehicle, but HO formation is greatly diminished in Palovarotene-treated companions by more than 80% based on bone volume/total volume quantification. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.412 ml | 12.062 ml | 24.123 ml |
5 mM | 0.482 ml | 2.412 ml | 4.825 ml |
10 mM | 0.241 ml | 1.206 ml | 2.412 ml |
5 mM | 0.048 ml | 0.241 ml | 0.482 ml |